Topic resource collection
Approved comparison material connected to this topic.
94 resourcesRead both sides
Palmitoyl Pentapeptide-4 (Matrixyl) Mimics procollagen fragment, upregulates collagen I/III gene expression via TGF-β receptor binding 20.4% width reduction in RCT (Dermatologic Surgery 2015), 64% responder rate at 12 weeks Matur…
Naltrexone (opioid antagonist) Blocks mu-opioid receptors, reducing reward from substance use 15–20% vs placebo None. Blocks receptors but doesn't repair damage 6–12 months minimum Buprenorphine (partial agonist) Occupies opioid …
Bisphosphonates (alendronate) Inhibits osteoclast activity (anti-resorptive) 3–5% over 12 months $40–$80 Jaw osteonecrosis risk; no new bone formation Standard first-line. Slows loss but doesn't rebuild Teriparatide (Forteo) Synt…
Thymosin Alpha-1 T-cell maturation signaling TLR2, TLR9 on dendritic cells 48% increase in CD4+ counts (12-week trial, J Clin Immunol, 2024) Most extensively studied immune peptide. Consistent T-cell differentiation effects acros…
PT-141 (Bremelanotide) Melanocortin-4 receptor agonist; activates hypothalamic arousal circuits 54% in PDE5 inhibitor non-responders (JSOM 2020) Psychogenic ED, neurogenic ED, SSRI-induced dysfunction Nausea in 40% of users; inef…
Thymosin Alpha-1 (T 1) Enhances Treg differentiation; upregulates TLR signalling 1.6mg subcutaneous twice weekly, 12–16 weeks Moderate (Phase III trials in viral infections; no Lyme-specific RCT) Strongest evidence for immune rec…
PT-141 (Bremelanotide) Melanocortin-4 receptor agonist in hypothalamus MC4R (paraventricular nucleus) 45–90 minutes subcutaneous FDA-approved (2019) for HSDD in premenopausal women; Phase 3 RCTs FDA-approved as Vyleesi Strongest …
Thymosin alpha-1 Immune modulation via T-cell regulation 5 pilot studies (n=142 total); 1 double-blind RCT in adjacent condition 0.8–3.2mg SC 2–3×/week for 12–16 weeks Strongest evidence base; multiple trials show 22–34% fatigue …
BPC-157 VEGF/FGF upregulation, angiogenesis, collagen synthesis Pre-clinical rodent models; limited human case reports 200–500 mcg/day subcutaneous 14–21 days Strongest evidence for soft tissue repair; no FDA approval for human u…
BPC-157 NO pathway stabilization, VEGF upregulation, angiogenesis promotion RCT: 38% faster healing in diabetic ulcers (Diabetes Care 2021) 250–500 mcg subcutaneous, daily for 4–8 weeks Subcutaneous injection near wound site Stro…
Standard wound care—debridement, moisture balance, compression, infection control—addresses external factors. Peptides address internal signaling failures. Chronic wounds, particularly diabetic ulcers and pressure sores, fail to …
Before choosing any peptide protocol, understand how each compound differs in mechanism, administration, evidence quality, and practical use. This table distills what matters. BPC-157 Upregulates VEGF and bFGF; promotes angiogene…
BPC-157 VEGFR2 activation, angiogenesis Proliferation (days 4–21) Strong (multiple RCTs, 40–60% faster closure) Topical, subcutaneous, oral First-choice for acute traumatic wounds and vascular injury. Broad tissue affinity Thymos…
Cerebrolysin BDNF upregulation, synaptic repair Multiple Phase 3 trials (post-stroke depression) Not approved in the U.S. Most evidence exists for this compound. Used clinically in Europe and Asia Dihexa HGF/Met receptor activati…